Previous 10 | Next 10 |
On Monday, March 30, a district court judge in Nevada ruled in favor of two generic drug companies seeking to invalidate patents covering Vascepa, a fish oil product developed and marketed by Amarin (NASDAQ: AMRN) . Investors witnessed $3.3 billion in valuation go up in smoke as the stock plu...
When the U.S. Food and Drug Administration approved a widened use for Amarin 's (NASDAQ: AMRN) cardiovascular drug Vascepa in December, hopes were high that it could turn into a blockbuster. However, a court ruling may have burst that bubble this week. Amarin shares sank 70% after a...
The coronavirus outbreak and the effects of COVID-19 have gone deeper and wider than most people would have expected. That applies just as much to markets as anywhere. Whether it's a tech sector that is supporting our new work from home or re-rating as expensive EV/Sales multiples make less se...
Dr. Ashok Dutta of Avisol Capital Partners, which runs the Total Pharma Tracker or TPT on Seeking Alpha's Marketplace, recently reached out to Mr. Zachary Silbersher, a key legal expert on the Amarin ( AMRN ) legal situation, to ask him for some clarity on the lawsuit and the upcoming appeal...
Amarin Corporation ( AMRN ) is based in Dublin, Ireland and its U.S. headquarters is in Bridgewater, New Jersey. Its key product is Vascepa, which is eicosapentaenoic acid, EPA, a component of fish-oil derived omega-3 fatty acids. Vascepa was recently FDA approved to reduce cardiovascular ...
Investing in the middle of a global pandemic is tricky, to be sure. Scores of companies are going to post dreadful first-, second-, and perhaps even third-quarter earnings this year. The market, in turn, has been adjusting to this harsh reality by shrinking valuations almost across the board. Bu...
In a note, Cowen's Ken Cacciatore (Outperform/$8) says Amarin (NASDAQ: AMRN ) could be worth $20 a share based on $10 on Vascepa sales in Europe and $10 upon a successful appeal of the recent patent ruling opening the door for generic competition. More news on: Amarin Corporation plc, Merc...
On Monday, Amarin (NASDAQ: AMRN) investors got some horrible news. A federal judge in Nevada declared that the company's intellectual property was "obvious" and its drug patent was invalid . This was a complete shock to many investors, including yours truly. Amarin only has one drug, ...
Amarin ( AMRN ) lost a patent lawsuit against generics Hikma and Dr Reddy's ( RDY ) at the District Court of Judge Miranda Du. Judge Du said that while the generics (will) infringe on Amarin's (MARINE trial related) patents, the infringement will not matter because these patents are invalidate...
Penny Stocks To Watch During Q2 2020 Penny Stocks are some of the most sought after equities by day traders. Aside from options, these cheap stocks are some of the only ones that can generate massive returns within a matter of hours. Given that volatility, they’re not for everyone. Bu...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...